<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026789</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000848</org_study_id>
    <nct_id>NCT04026789</nct_id>
  </id_info>
  <brief_title>Medication Abortion for Pregnancy of Unknown Location</brief_title>
  <acronym>MAPUL</acronym>
  <official_title>Medication Abortion for Pregnancy of Unknown Location</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood League of Massachusetts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Planned Parenthood League of Massachusetts</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare time to completed abortion between two protocols for&#xD;
      patients seeking medication abortion - same-day start versus delay-for-diagnosis - in the&#xD;
      setting of asymptomatic, low-risk, pregnancy of unknown location.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial (plus prospective cohort for those interested in participation but unwilling to be randomized)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to completed abortion</measure>
    <time_frame>through study completion, an average of two weeks</time_frame>
    <description>Time to completed abortion as defined by the number of days between initial ultrasound diagnosis of PUL to the diagnostic test that confirms complete abortion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with complete expulsion of pregnancy without surgical intervention</measure>
    <time_frame>14 days after initiation of medical abortion</time_frame>
    <description>Efficacy of medical abortion, defined as number of participants with complete expulsion of pregnancy without surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis of pregnancy outcome</measure>
    <time_frame>Within 2 weeks of identification of pregnancy of unknown location on ultrasound</time_frame>
    <description>Number of days between initial ultrasound diagnosis of pregnancy of unknown location and diagnosis of pregnancy outcome, with options including intrauterine pregnancy, ectopic pregnancy, or early pregnancy loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ectopic pregnancy</measure>
    <time_frame>Within 2 weeks of identification of pregnancy of unknown location on ultrasound</time_frame>
    <description>Rate of ectopic pregnancy among entire study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of participants who complete follow-up and confirm complete abortion</measure>
    <time_frame>Within 1 month of identification of pregnancy of unknown location on ultrasound</time_frame>
    <description>Percent of participants who adhered to recommended follow-up plan and confirmed a complete abortion through ultrasound or hCG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Same-day-start</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delay-for-diagnosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Same-day-start</intervention_name>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing</description>
    <arm_group_label>Same-day-start</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Delay-for-diagnosis</intervention_name>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion</description>
    <arm_group_label>Delay-for-diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with an undesired pregnancy of less than or equal to 42 days gestation based on&#xD;
        last menstrual period (LMP) who present to Planned Parenthood League of Massachusetts&#xD;
        (PPLM)'s Greater Boston Health Center seeking medication abortion will be considered for&#xD;
        study participation.&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Positive urine or serum hCG test&#xD;
&#xD;
          -  No evidence of gestational sac on transvaginal ultrasound&#xD;
&#xD;
          -  Desire for medication abortion as method of pregnancy termination&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Ineligible for medication abortion at PPLM based on current PPLM clinical guidelines&#xD;
&#xD;
          -  Reasonable clinical suspicion for ectopic or molar pregnancy, such as abnormal or&#xD;
             concerning ultrasound findings&#xD;
&#xD;
          -  High risk for ectopic pregnancy, such as prior ectopic pregnancy, history of tubal&#xD;
             surgery, concurrent intrauterine device in place during this pregnancy&#xD;
&#xD;
          -  Exhibiting symptoms of possible ectopic, such as vaginal bleeding or abdominal pain&#xD;
&#xD;
          -  LMP &gt; 42 days or unknown LMP&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Prior participation in this study&#xD;
&#xD;
          -  Anticipated inability to present for scheduled follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Principal Investigator</last_name>
    <phone>6176161600</phone>
    <email>research@pplm.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>PPLM</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
      <phone>617-616-1600</phone>
      <email>research@pplm.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share individual participant data with any other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

